Demographics and clinical characteristics for patients with SLE and HC. Values are n (%) or mean ± SD unless otherwise specified.
| Characteristics | Patients, n = 58 |
|---|---|
| M/F | 0/58 |
| Age at diagnosis, yrs, mean ± SD (range) | 32 ± 12.3 (14–64) |
| Age at inclusion, yrs, mean ± SD (range) | 46.1 ± 13.1 (24–69) |
| Danish ethnicity | 58 (100) |
| Hydroxychloroquine treatment | 45 (78) |
| Prednisolone treatment | 22 (38) |
| Mycophenolate mofetil | 6 (10) |
| Azathioprine | 10 (17) |
| No treatment | 6 (10) |
| ACR criteria | |
| Malar rash, ACR-1 | 27 (46.6) |
| Discoid rash, ACR-2 | 11(19.0) |
| Photosensitivity, ACR-3 | 28 (48.3) |
| Oronasal ulcers, ACR-4 | 13 (22.4) |
| Arthritis, ACR-5 | 46 (79.3) |
| Serositis, ACR-6 | 14 (24.1) |
| Nephritis, ACR-7 | 7 (12.1) |
| CNS, ACR-8 | 4 (6.89) |
| Hematological, ACR-9 | 33 (57.0) |
| Immunological, ACR-10 | 46 (79.3) |
| ANA, ACR-11 | 57 (98.3) |
| Present anti-dsDNA level, × 103 IU/l | 33.3 ± 15.7 |
| Disease activity/organ damage | |
| SLEDAI | 6.48 ± 4.03 |
| SDI | 1.72 ± 1.56 |
| HC characteristics | |
| M/F | 0/65 |
| Age, yrs, mean ± SD (range) | 44.03 ± 12.2 (21–64) |
SLE: systemic lupus erythematosus; HC: healthy controls; ACR: American College of Rheumatology; CNS: central nervous system; ANA: antinuclear antibody; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SDI: Systemic Lupus International Collaborating Clinics/ACR Damage Index.